UBS upgraded GE HealthCare (GEHC) to Neutral from Sell with a price target of $73, down from $74. The company last week cut its 2025 earnings guidance by 15% driven by tariffs, the analyst tells investors in a research note. The firm says the news, combined with a 28% pullback in the shares since September 2024 and a shift in the narrative around China towards a more skeptical stance from investors on the growth outlook of that business, means GE HealthCare’s risk/reward “has shifted.” A “reasonable worst case outlook is now baked into guidance and the share price,” meaning UBS no longer sees material downside, contends the analyst.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare upgraded to Neutral from Sell at UBS
- Johnson & Johnson Stock (JNJ) Perks Up as it Mulls $2.5B Purchase of Sonic Beam Cancer Fighting MedTech
- GE HealthCare announces intended expansion of radiation oncology portfolio
- GE HealthCare participates in a conference call with JPMorgan
- Strong Q1 Performance and Strategic Initiatives Drive Buy Rating for GE Healthcare Technologies Inc